ArticleFuture oncology (London, England)2025

Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP).

Alicia K Morgans et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.